This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Terns has a modest market cap of less than $800 million, and its possible upside could be massive.
| Ticker |
Sentiment |
Impact |
|
VKTX
|
Neutral
|
11 %
|
|
TERN
|
Neutral
|
38 %
|
|
GS
|
Neutral
|
6 %
|
|
NVO
|
Neutral
|
11 %
|
